These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27724908)

  • 21. A rapid and low-cost microscopic observation drug susceptibility assay for detecting TB and MDR-TB among individuals infected by HIV in South India.
    Solomon S; Balakrishnan P; Vignesh R; Waldrop G; Solomon SS; Murugavel KG; Kumarasamy N; Yepthomi T; Poongulali S; Swathirajan CR; Sreenivasan V; Chandrasekar C; Suriakumar J; Mahilmaran A; Manoharan G; Moore DA
    Indian J Med Microbiol; 2013; 31(2):130-7. PubMed ID: 23867668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Microscopic Observation Drug Susceptibility (MODS) and the string test for rapid diagnosis of pulmonary tuberculosis in HIV/AIDS patients in Bolivia.
    Lora MH; Reimer-McAtee MJ; Gilman RH; Lozano D; Saravia R; Pajuelo M; Bern C; Castro R; Espinoza M; Vallejo M; Solano M; Challapa R; Torrico F
    BMC Infect Dis; 2015 Jun; 15():222. PubMed ID: 26047953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia.
    Kaso AW; Hailu A
    PLoS One; 2021; 16(10):e0259056. PubMed ID: 34695153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study.
    Zar HJ; Workman L; Isaacs W; Dheda K; Zemanay W; Nicol MP
    Lancet Glob Health; 2013 Aug; 1(2):e97-e104. PubMed ID: 25104164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.
    Choi HW; Miele K; Dowdy D; Shah M
    Int J Tuberc Lung Dis; 2013 Oct; 17(10):1328-35. PubMed ID: 24025386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xpert MTB/RIF test for tuberculosis.
    Salvo F; Sadutshang TD; Migliori GB; Zumla A; Cirillo DM
    Lancet; 2011 Aug; 378(9790):481-2; author reply 482-3. PubMed ID: 21821177
    [No Abstract]   [Full Text] [Related]  

  • 27. Outcomes of a clinical diagnostic algorithm for management of ambulatory smear and Xpert MTB/Rif negative HIV infected patients with presumptive pulmonary TB in Uganda: a prospective study.
    Walusimbi S; Semitala F; Bwanga F; Haile M; De Costa A; Davis L; Joloba M; Hoffner S; Kamya M
    Pan Afr Med J; 2016; 23():154. PubMed ID: 27303572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reassessment of the positive predictive value and specificity of Xpert MTB/RIF: a diagnostic accuracy study in the context of community-wide screening for tuberculosis.
    Ho J; Nguyen PTB; Nguyen TA; Tran KH; Van Nguyen S; Nguyen NV; Nguyen HB; Luu KB; Fox GJ; Marks GB
    Lancet Infect Dis; 2016 Sep; 16(9):1045-1051. PubMed ID: 27289387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Xpert MTB/RIF assay in children with presumed pulmonary tuberculosis in Papua New Guinea.
    Kasa Tom S; Welch H; Kilalang C; Tefuarani N; Vince J; Lavu E; Johnson K; Magaye R; Duke T
    Paediatr Int Child Health; 2018 May; 38(2):97-105. PubMed ID: 28490246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The transition to Xpert MTB/RIF ultra: diagnostic accuracy for pulmonary tuberculosis in Kampala, Uganda.
    Andama A; Jaganath D; Crowder R; Asege L; Nakaye M; Katumba D; Mukwatamundu J; Mwebe S; Semitala CF; Worodria W; Joloba M; Mohanty S; Somoskovi A; Cattamanchi A
    BMC Infect Dis; 2021 Jan; 21(1):49. PubMed ID: 33430790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis.
    van't Hoog AH; Cobelens F; Vassall A; van Kampen S; Dorman SE; Alland D; Ellner J
    PLoS One; 2013; 8(12):e82786. PubMed ID: 24367555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in children: a prospective, multi-centre evaluation.
    Reither K; Manyama C; Clowes P; Rachow A; Mapamba D; Steiner A; Ross A; Mfinanga E; Sasamalo M; Nsubuga M; Aloi F; Cirillo D; Jugheli L; Lwilla F
    J Infect; 2015 Apr; 70(4):392-9. PubMed ID: 25312863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the Xpert MTB/RIF Assay and Real-time PCR for the Detection of Mycobacterium tuberculosis.
    Kim MJ; Nam YS; Cho SY; Park TS; Lee HJ
    Ann Clin Lab Sci; 2015; 45(3):327-32. PubMed ID: 26116598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay.
    Shah NS; Moodley P; Babaria P; Moodley S; Ramtahal M; Richardson J; Heysell S; Li X; Moll A; Friedland G; Sturm AW; Gandhi NR
    Am J Respir Crit Care Med; 2011 May; 183(10):1427-33. PubMed ID: 21297071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling.
    Ejalu DL; Irioko A; Kirabo R; Mukose AD; Ekirapa E; Kagaayi J; Namutundu J
    BMJ Open; 2022 Aug; 12(8):e059823. PubMed ID: 35998960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV.
    Boyles TH; Griesel R; Stewart A; Mendelson M; Maartens G
    Int J Infect Dis; 2018 Oct; 75():67-73. PubMed ID: 30125689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved performance of Xpert MTB/RIF assay on sputum sediment samples obtained from presumptive pulmonary tuberculosis cases at Kibong'oto infectious diseases hospital in Tanzania.
    Mbelele PM; Aboud S; Mpagama SG; Matee MI
    BMC Infect Dis; 2017 Dec; 17(1):808. PubMed ID: 29284421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordance between MTB/RIF and Real-Time Tuberculosis-Specific Polymerase Chain Reaction Assay in Bronchial Washing Specimen and Its Clinical Implications.
    Jo YS; Park JH; Lee JK; Heo EY; Chung HS; Kim DK
    PLoS One; 2016; 11(10):e0164923. PubMed ID: 27760181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.